Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer

BACKGROUND AND OBJECTIVE: Several clinical trials have proven that icotinib hydrochloride, a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemot...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Onco Targets Ther
Prif Awduron: Shen, Yan-Wei, Zhang, Xiao-Man, Li, Shu-Ting, Lv, Meng, Yang, Jiao, Wang, Fan, Chen, Zhe-Ling, Wang, Bi-Yuan, Li, Pan, Chen, Ling, Yang, Jin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2016
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
https://ncbi.nlm.nih.gov/pubmed/26966381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98363
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg